嵌合抗原受體-巨噬細胞(CAR-M)市場:相關利益者，技術，開發平台，聯盟，資金籌措

本報告提供全球嵌合抗原受體-巨噬細胞(CAR-M)市場相關調查，市場概要，以及CAR-M的技術評估，開發平台和標的，及加入此市場的主要企業簡介等資訊。

目錄

第1章 摘要整理

第2章 簡介

第3章 單球和巨噬細胞的生物學

第4章 CAR-M形勢分析

• 企業評估
  • 公司概要
  • 融資
  • 聯盟
• CAR-M技術評估
  • 自體CAR-M技術
  • 同類CAR-M技術
• CAR-M開發平台，標的，及概念驗證的評估

第5章 企業簡介

• Carisma Therapeutics
• CellOrigin Biotech
• Evotec
• Fate Therapeutics
• Inceptor Bio
• Myeloid Therapeutics
• Shoreline Biosciences
• Thunder Biotech

第6章 技術簡介

• ATAK CAR單球
• CAR-iMAC技術
• CAR-M平台
• iPSC CAR巨噬細胞(iMAC)技術

第7章 CAR-M細胞療法的候補簡介

• CT-0508
• CT-0525
• CT-1119
• MT-101
• MT-102
• MT-301
• MT-302

第8章 參考文件

This report provides you with a landscape description and analysis of chimeric antigen receptor-macrophage (CAR-M) platform technologies and stakeholders from an industry perspective as of February 2023. CAR-M cell therapy is an approach to overcome the limitations and obstacles of CAR T-cell and CAR natural killer (NK) cell therapy. CAR-macrophages bring several unique benefits. CAR-macrophages can effortlessly submerge in the cancer environment. Additionally, CAR-macrophages can decrease the ratio of tumor-associated macrophages (TAMs) and switch the phenotype of TAMs. Moreover, CAR-macrophages play a phagocytic role in tumor cells, facilitate antigen presentation and augment the cytotoxicity of T cells. Finally, CAR-macrophages have less toxicity and limited circulation time than T cells.

Two main approaches for CAR-M cell therapy are:

Autologous CAR-M cell therapy with ex vivo manufacturing or in vivo engineering of monocytes;

Allogeneic CAR-M therapy based in induced pluripotent stem cells (iPSC).

The report brings you up-to-date with information about and analysis of:

Approaches for autologous and allogeneic CAR-m cell therapy;

Stakeholders in the field, i.e. technology companies, pharmaceutical partners and investors;

Technologies of CAR-M construction and manufacturing;

Delivery technologies: viral vectors; electroporation; lipid nanoparticles (LNPs)

Pipeline of autologous ex vivo/in vivo and allogeneic CAR-M cell therapy candidates;

Targets of CAR-M cell therapy candidates;

Proof-of-Concept with CAR-M cell therapy candidates;

Financing history and financial situation of CAR-M companies;

Partnering deals (discovery and/or development collaborations, licensing, acquisitions);

Comparative assessment.

Methodology:

This report is based on information retrieved for CAR-M technology companies and partner companies regarding discovery and development collaborations, technology in- and out-licensing and manufacturing arrangements. All information is fully referenced, either with scientific references (conference abstracts, Posters, presentations, full paper) or hyperlinks leading to the source of corporate information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.

Details about R&D strategy, collaboration and licensing agreements, acquisitions, financing rounds and sources are described in the company profiles. For each CAR-M technology company, a profile has been elaborated providing information about the company background/history, the financial situation, relevant technology, partnering deals and target & pipeline overview.

Detailed description of CAR-M technologies from four companies is provided in the "CAR-M Technology Profiles" chapter. A general overview of CAR-M technologies from the other companies can be found in the respective company profile.

Eventually, this report has profiled seven CAR-M cell therapy candidates in preclinical and clinical stages of R&D. The descriptions can be found in the chapter "CAR-M Cell Therapy Candidate Profiles" in alphabetical order by the drug code.

A detailed CAR-M Industry Landscape Analysis precedes the three profile chapters with evaluations of the companies, CAR-M technologies and the CAR-M pipeline with targets and information about preclinical and clinical experience.

What will you find in the report?

Profiles of pure-play and diversified CAR-M technology companies;

Comprehensive description and analysis of emerging autologous and allogeneic CAR-M technologies;

Pharmacologic profiles of CAR-M cell therapy candidates;

Target selection, pipeline analysis and competition of CAR-M cell therapy candidates;

Description and analysis of financing rounds (capital raised, investors);

Economic terms of collaboration and licensing deals;

Sources of financing.

Who will benefit from the report?

Venture capital, private equity and investment managers;

Managers of Big Pharma venture capital firms;

Financial analysts;

Business development and licensing (BDL) specialists;

CEO, COO and managing directors;

Corporate strategy analysts and managers;

Chief Technology Officer;

R&D Portfolio, Technology and Strategy Management;

Clinical and preclinical development specialists;

Cell therapy specialists

Table of Contents

Table of Contents

Frequent Abbreviations

1 Executive Summary

2 Introduction

3 Monocyte and Macrophage Biology

4 CAR-M Landscape Analysis

• 4.1 Company Evaluations
  • 4.1.1 Corporate Overview
  • 4.1.2 Financing
  • 4.1.3 Partnering
• 4.2 CAR-M Technology Evaluations
  • 4.2.1 Autologous CAR-M Technologies
  • 4.2.2 Allogeneic CAR-M Technologies
• 4.3 Evaluation of CAR-M Pipeline, Targets and Proof-of-Concept

5 Company Profiles

• 5.1 Carisma Therapeutics
• 5.2 CellOrigin Biotech
• 5.3 Evotec
• 5.4 Fate Therapeutics
• 5.5 Inceptor Bio
• 5.6 Myeloid Therapeutics
• 5.7 Shoreline Biosciences
• 5.8 Thunder Biotech

6 Technology Profiles

• 6.1 ATAK CAR Monocytes
• 6.2 CAR-iMAC Technology
• 6.3 CAR-M Platform
• 6.4 iPSC CAR Macrophage (iMAC) Technology

7 CAR-M Cell Therapy Candidate Profiles

• 7.1 CT-0508
• 7.2 CT-0525
• 7.3 CT-1119
• 7.4 MT-101
• 7.5 MT-102
• 7.6 MT-301
• 7.7 MT-302

8 References

Tables in the Text

Figures & Tables

Tables in the Text

• Table 1 Key Corporate Characteristics of Companies with CAR-M Technologies
• Table 2 Financing of Companies with CAR-M Technology
• Table 3 Product Partnering of CAR-M Companies
• Table 4 Technology and Manufacturing Partnering of CAR-M Companies
• Table 5 Overview of CAR-M Technologies at Carisma Therapeutics and Myeloid Therapeutics
• Table 6 Overview of Research Stage iPSC & CAR-iMac Technologies in Industry Development
• Table 7 CAR-M Pipeline: Targets, Constructs and R&D Stage
• Table 8 CAR-M Pipeline of Carisma Therapeutics
• Table 9 Myeloid Therapeutics' Pipeline of Product Candidates